In turn, silencing sCD137 expression in malignant cells promoted T cell-mediated anti-tumor immunity, particularly through CD8+ T cells, leading to reduced tumor progression and, in some cases, complete tumor rejection in vivo. Here, CD8A is linked to neoplasm.